Credit: UPMC PITTSBURGH, May 17, 2021 – Monoclonal antibodies, a COVID-19 treatment given early after coronavirus infection, cut the risk of hospitalization and death by 60%...
Europe's medicines regulator said on May 7 the EMA has begun a real-time review of the Covid-19 antibody treatment developed by GSK and Vir Biotechnology,, formally...
In this eBook, sponsored by Sartorius, we highlight the research efforts and related applications utilized to study binding affinity, potency and target specificities of neutralizing antibodies...
Adeno-associated virus (AAV) vectors are the leading vectors for gene delivery. AAV vectors pose challenges including costly manufacture, high percentages of empty capsids, and safety issues...
CloseCloseCloseHealthcare has been lagging the market, but that is now changing.As biotechs consolidate, other healthcare industry groups are powering the sector to a breakout.Medical Devices and...
The developments are coming in thick and fast at Sorrento Therapeutics (SRNE). Recent times have seen a flurry of announcements regrading the company’s bulging pipeline. Earlier...
The European Medicines Agency will conduct an accelerated review of Eli Lilly and Co.'s rheumatoid arthritis drug Olumiant for hospitalized Covid-19 patients getting oxygen, the EU...
The EMA has started reviewing the emergency use application for GlaxoSmithKline and Vir Biotech’s COVID-19 antibody VIR-7831, which The post EMA starts review of GSK/Vir COVID-19...
A phase 3 trial of Romark’s antiviral drug NT-300 has missed the main objective in a phase 3 The post Romark eyes FDA okay for COVID...
Immunosuppressive drugs for inflammatory diseases like rheumatoid arthritis, multiple sclerosis and ulcerative colitis can impair the body's response to the Covid-19 vaccines from Pfizer/BioNTech and Moderna,...
Paris-based Sanofi bought Cambridge, Massachusetts-based Tidal Therapeutics in a deal totaling $470 million.
Portable platform detects early biomarkers of the Ebola virus faster than PCR, the current industry standard Credit: Michaela Kane, Duke University DURHAM, N.C. — An interdisciplinary...
By blocking human enzyme cathepsin L, chemical inhibitor K777 reduces coronavirus’ ability to infect cell lines; clinical trials are underway Credit: National Institute of Allergy and...
Pfizer and BioNTech on March 31 announced data from a Phase III study which showed 100 percent efficacy and robust antibody responses in patients ages 12-15 years...
Relief Therapeutics Holding AG (OTC: RLFTF) is making a powerful run northbound after NeuroRx reported ZYESAMI™ met the primary endpoint in its Phase 2b/3 trial* for...
Antibody treatments from Eli Lilly and Vir Biotechnology reduced viral load in low-risk Covid-19 patients, results from a mid-stage trial showed on March 29.
The U.S. government has halted distribution of Eli Lilly’s COVID-19 antibody treatment bamlanivimab as a monotherapy just four months after it received FDA emergency use authorization,...
Credit: UPMC PITTSBURGH, March 26, 2021 – As evidence mounts supporting the use of monoclonal antibody treatment to reduce hospitalizations and deaths from COVID-19, UPMC and...
The U.S. government has halted distribution of Eli Lilly’s COVID-19 antibody treatment bamlanivimab as a monotherapy just four months after it received FDA emergency use authorization,...
GSK and Vir Biotechnology filed an application to U.S. regulators for emergency use authorization of their antibody therapy to treat early-stage Covid-19 infections, the drugmakers said...
In announcing the halt this week, the U.S. Office of the Assistant Secretary for Preparedness and Response (ASPR) said it will continue to distribute bamlanivimab in...
AstraZeneca will supply up to half a million extra doses of the company's experimental antibody-based Covid-19 combination therapy to the United States, in a bright spot...
Newly announced data from Eli Lilly’s Phase III BLAZE-1 clinical trial show a combination of two of the company’s monoclonal antibodies, bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016),...
Credit: Vanderbilt University Medical Center A monoclonal antibody “cocktail” developed at Vanderbilt University Medical Center (VUMC) to neutralize the COVID-19 virus is effective against all known...
Worrisome new coronavirus variants can evade antibodies that neutralize original virus Credit: Matt Miller/Washington University New research at Washington University School of Medicine in St. Louis...
New immunotherapy developments include the use of tumor-infiltrating lymphocytes, allogeneic T cells, co-stimulatory signals, and engineered cytokines. The post Reinforcing the Body’s Defenses against Cancer appeared...
Vir Biotechnology and GlaxoSmithKline said they will pause enrollment into a study testing their experimental Covid-19 antibody therapy
But researchers say tocilizumab, a monoclonal antibody treatment, may reduce ventilator use and shorten hospital stays Credit: Photo courtesy of Roche In a study published online...
There is still no cure for COVID-19, but doctors have several innovative treatments. Some are keeping patients out of the hospital entirely.
Regeneron Pharmaceuticals said an independent panel found the company’s Covid-19 antibody cocktail to have “clear clinical efficacy” in reducing the rates of hospitalization and deaths in...